Core Insights - ZyVersa Therapeutics, Inc. is focused on developing first-in-class drugs for renal and inflammatory diseases, particularly targeting type 2 diabetes mellitus (T2DM) and its macrovascular complications [1][2] - The company is advancing its Inflammasome ASC Inhibitor IC 100, which aims to control inflammation linked to T2DM and associated cardiovascular conditions [2][4] Industry Context - T2DM affects over 530 million people globally and is associated with significant cardiovascular complications, making it a leading cause of disability and death [4] - In 2021, global healthcare expenditures for T2DM exceeded $960 billion, highlighting the urgent need for effective therapies [2] Research Findings - A peer-reviewed article indicates that the NLRP3 inflammasome is a key mediator of metabolic inflammation, contributing to the development and progression of T2DM and its cardiovascular complications [1][3] - The review emphasizes that targeting inflammasomes could be a transformative strategy for reducing inflammation in T2DM and improving cardiovascular outcomes [6] Product Development - ZyVersa's IC 100 has shown preclinical efficacy in reducing insulin resistance, inflammation, and plaque buildup in various models related to cardiometabolic conditions [4] - The company plans to initiate an IND-enabling preclinical study for IC 100 in a diet-induced obesity model in Q4-2025, with results expected in Q1-2026 [2]